# Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

> **NCT00096616** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 113 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Combivent® CFC MDI
- **DRUG:** Albuterol HFA MDI

## Key facts

- **NCT ID:** NCT00096616
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096616, "Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00096616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*